Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Taxes (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Change in Taxes for 12 consecutive years, with -$65.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Taxes fell 14326.32% year-over-year to -$65.8 million, compared with a TTM value of -$32.4 million through Dec 2025, down 4669.58%, and an annual FY2025 reading of -$32.0 million, down 3315.98% over the prior year.
  • Change in Taxes was -$65.8 million for Q3 2025 at Enanta Pharmaceuticals, down from $31.9 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $31.9 million in Q2 2025 and bottomed at -$65.8 million in Q3 2025.
  • Average Change in Taxes over 5 years is -$518526.3, with a median of $297000.0 recorded in 2024.
  • The sharpest move saw Change in Taxes skyrocketed 50970.0% in 2023, then crashed 14326.32% in 2025.
  • Year by year, Change in Taxes stood at -$8.5 million in 2021, then surged by 99.82% to -$15000.0 in 2022, then soared by 4966.67% to $730000.0 in 2023, then crashed by 39.04% to $445000.0 in 2024, then crashed by 14882.92% to -$65.8 million in 2025.
  • Business Quant data shows Change in Taxes for ENTA at -$65.8 million in Q3 2025, $31.9 million in Q2 2025, and $1.4 million in Q1 2025.